MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijantimicag.2026.107825

Медицинская библиотека · International journal of antimicrobial agents · 2026

Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

Perez-Valero Ignacio, Corona Mata Diana, Crussells Canales María Jose, Velasco Arribas Maria, Mican Rivera Rafael, Ryan Pablo, Navarrete-Lorite Miguel Nicolas, Tiraboschi Juan, Barrado-Cuchillo Julia, Molero Bonilla Marta, Artigues Serra Francisca, Mena de Cea Alvaro, de la Fuente Moral Sara, Perez Stachowski Xavier, Garcia Fraile Lucio Jesus, Diaz Almidon Mariana, Gil Pedro, Ferreira Tata Claudia, Rivero Juarez Antonio, Rivero Antonio

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование IV фазыПеревод в очереди

Аннотация

OBJECTIVE

To evaluate if switching from dolutegravir/lamivudine (DTG/3TC) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) improves neuropsychiatric tolerability in suppressed adults with stable neuropsychiatric comorbidities.

METHODS

MIND was a phase IV, randomised, double-blind, multicentre trial. Participants were assigned (1:1) to switch to BIC/FTC/TAF or continue DTG/3TC. The primary endpoint was the proportion of grade 2-4 neuropsychiatric adverse events (NP-AEs) at week 24. Secondary endpoints included safety, virological maintenance, and patient-reported outcomes (PROs) through week 48.

RESULTS

Eighty participants were randomised (BIC/FTC/TAF, n = 41; DTG/3TC, n = 39). At week 24, grade 2-4 NP-AEs occurred in 14.6% of the BIC/FTC/TAF arm vs 17.9% in the DTG/3TC group (difference: 3.3% [95%CI -19.5 to 12.9]; P = 0.688). At week 48, incidences were 21.9% vs 17.9% (difference: 4.0% [95%CI -13.5 to 21.5]; P = 0.650). NP-AE-related discontinuations were low (7.3% vs 5.1%). At week 24, BIC/FTC/TAF showed less moderate-to-severe nausea/vomiting (3.8% vs 23.2%; P = 0.027) and abdominal discomfort (16.8% vs 40.2%; P = 0.04). At week 48, BIC/FTC/TAF reported more headache (55.7% vs 26.1%; P = 0.03) but fewer skin symptoms (24.9% vs 49.2%; P = 0.022). All maintained virological suppression at week 48; four participants on DTG/3TC met failure criteria but achieved re-suppression without emergent resistance. PRO trajectories and treatment satisfaction remained high and stable throughout the study, with no significant between-group differences.

CONCLUSIONS

In PLWH with stable neuropsychiatric comorbidities, switching to BIC/FTC/TAF did not reduce NP-AEs or improve PROs versus continuing DTG/3TC. Both regimens were safe and highly effective at maintaining virological suppression through 48 weeks.

TRAIL NUMBER: NoEUDRACT:2021-005927-19.

Для цитирования: Perez-Valero Ignacio, Corona Mata Diana, Crussells Canales María Jose, Velasco Arribas Maria, Mican Rivera Rafael, Ryan Pablo, Navarrete-Lorite Miguel Nicolas, Tiraboschi Juan, Barrado-Cuchillo Julia, Molero Bonilla Marta, Artigues Serra Francisca, Mena de Cea Alvaro, de la Fuente Moral Sara, Perez Stachowski Xavier, Garcia Fraile Lucio Jesus, Diaz Almidon Mariana, Gil Pedro, Ferreira Tata Claudia, Rivero Juarez Antonio, Rivero Antonio. Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.. International journal of antimicrobial agents. 2026. DOI: 10.1016/j.ijantimicag.2026.107825.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.